Ambipar says it hopes to conclude the merger process between Response and HPX soon

Ambipar announced that it filed the third protocol, being the first public, before the United States Securities and Exchange Commission (SEC) of the merger between Ambipar Response and the specific purpose acquisition company (Spac, in the acronym in English) in English) HPX.

The operation, originally announced in July, foresees the listing of Ambipar Response on the New York Stock Exchange (NYSE) in a company with a “pro forma” value of R$ 3.1 billion, including debts. Ambipar will remain the majority shareholder, with 96.2% of the voting capital.

“This is an important development for the SEC registration process (‘closing’) which we expect to conclude soon”, says the company… learn more at Valor Econômico 15/12/2022

• Click here and read this article in full at Valor Econômico;
• Click here and read this article in full in Mergers & Acquisitions.